GRI Bio (NASDAQ

GRI) Announces Corporate Rebranding and Launch of New Website

Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases

LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced its new corporate branding and launch of its new corporate website, gribio.com.

“As we continue to evolve as a company, expand our awareness and reach in the public investment markets and advance our clinical development programs, we believed it was an important step to align our corporate branding identity and website with the vision we have for GRI Bio. We remain committed to advancing our leading NKT platform technology, which we believe holds an opportunity for all stakeholders as well as the potential for significant value creation. Over the course of the past several months, we have made encouraging progress on all fronts and are laser focused on successfully executing a number of value-driving milestones. We are excited to take this next step in the evolution of our Company and position ourselves to unlock further potential,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

Please click on the following link for a video message from Dr. Hertz discussing the Company’s rebranding: https://gribio.com/video613

The Company is currently advancing its lead development program GRI-0621, a type 1 invariant NKT (iNKT) antagonist, as a once-daily oral capsule for the treatment of idiopathic pulmonary fibrosis (IPF) with the potential to expand into additional fibrotic indications. In multiple disease models and preliminary data from trials to date¹improvement in fibrosis, liver function tests (LFTs), and other markers of inflammation and injury in patients were observed. GRI Bio plans to leverage the 505(b)(2) regulatory pathway to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF, expected to commence in the second half of 2023.

The Company’s second lead asset, GRI-0803, is a novel activator of human type 2 NKT cells currently in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus (SLE). Additionally, with a library of over 500 proprietary compounds, GRI has the potential to fuel a growing pipeline. The Company has ongoing evaluations for pipeline expansion opportunities targeting potential indications in multiple sclerosis, inflammatory bowel disease, and additional autoimmune indications.